Beer Sheva, Israel

Yana Yudilevich


Average Co-Inventor Count = 4.4

ph-index = 1


Company Filing History:


Years Active: 2021-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yana Yudilevich: Innovator in Low Intensity Ultrasound Therapy

Introduction

Yana Yudilevich is a prominent inventor based in Beer Sheva, Israel. She has made significant contributions to the field of medical technology, particularly in the area of low intensity ultrasound therapy. With a total of 2 patents, her work focuses on innovative methods for treating diseases associated with hyperproliferating cells.

Latest Patents

Yana's latest patents include groundbreaking methods for treating subjects suffering from diseases linked to hyperproliferating cells. One patent details a method that involves irradiating these cells with low-frequency ultrasound at an intensity below the cavitational threshold. This approach not only targets the hyperproliferating cells but also allows for the adjustment of ultrasound intensity based on the elasticity of the cells. Another patent outlines a non-invasive method for administering low intensity ultrasound to selectively prevent the growth of hyperproliferating cells while preserving the viability of normal cells.

Career Highlights

Throughout her career, Yana has worked with notable organizations such as B.G. Negev Technologies and Applications Ltd. and the Ben-Gurion University of the Negev Research and Development Authority. Her work in these institutions has furthered the development of her innovative therapies and has contributed to advancements in medical technology.

Collaborations

Yana has collaborated with esteemed colleagues, including Joseph Kost and Aharon Azaguri. These partnerships have played a crucial role in the development and refinement of her patented methods.

Conclusion

Yana Yudilevich stands out as a leading inventor in the field of low intensity ultrasound therapy. Her innovative approaches and dedication to medical advancements continue to make a significant impact in the treatment of diseases associated with hyperproliferating cells.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…